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Abstract 
Recent  increases  in  the  dosages  of  the
essential  antituberculosis  agents  isoniazid
(INH), rifampicin (RMP), pyrazinamide (PZA)
for  use  in  children  recommended  by  World
Health  Organization  have  raised  concerns
regarding the risk of hepatotoxicity. Published
data relating to the incidence and pathogene-
sis  of  antituberculosis  drug-induced  hepato-
toxicity  (ADIH),  particularly  in  children,  is
reviewed. Amongst 12,708 children receiving
chemoprophylaxis, mainly with INH, but also
other combinations of INH, RMP and PZA only
1 case (0.06%) of jaundice was recorded and
abnormal liver functions documented in 110
(8%) of the 1225 children studied. Excluding
tuberculous meningitis (TBM) 8984 were chil-
dren treated for tuberculosis disease  and jaun-
dice documented in 75 (0.83%) and abnormal
liver function tests in 380 (9.9%) of the 3855
children  evaluated.  Amongst  717  children
treated for TBM, however, jaundice occurred in
72 (10.8%) and abnormal LFT were recorded in
174 (52.9%) of those studied. Case reports doc-
ument the occurrence of ADIH in at least 63
children. Signs and symptoms of ADIH were
frequently ignored in the recorded cases. ADIH
can  occur  in  children  at  any  age  or  at  any
dosage of INH, RMP or PZA, but the incidence
of.ADIH is is considerably lower  in children
than  in  adults.  Children  with  disseminated
forms of disease are at greater risk of ADIH.
The use of the higher dosages of INH, RMP and
PZA recently recommended by WHO is unlike-
ly to result in a greater risk of ADIH in chil-
dren. 
Introduction
All  pharmacological  interventions  balance
efficacy and toxicity; there are few efficacious
agents that do not have some toxicity risk. In
the case of antituberculosis agents the major
risk is hepatotoxicity and three agents identi-
fied by World Health Organization (WHO) as
essential, isoniazid (INH), rifampicin (RMP)
and pyrazinamide (PZA), carry such a risk. In
view of recent recommendations for increased
dosages  of  INH  (5-15  mg/kg),  RMP  (10-20
mg/kg) and PZA (30-40 mg/kg) for children,1
this paper reviews knowledge of antituberculo-
sis drug induced hepatotoxicity (ADIH) occur-
ring amongst children. The role of the essen-
tial  drugs  INH,  RMP  and  PZA  implicated  in
ADIH is considered alone and in concert and
factors  that  might  influence  ADIH  in  adults
and children are discussed and literature relat-
ing to ADIH in children is reviewed and sum-
marized. 
Materials and Methods
A PubMed search used keywords hepatotox-
icity,  hepatitis,  liver  injury,  antituberculosis
treatment,  chemoprophylaxis,  chemotherapy,
isoniazid,  rifampin  and  rifampicin,  pyrazi-
namide, childhood, children and paediatric. All
papers published from 1944 up to December
2009 referring to children in the title or pub-
lished in paediatric journals were reviewed. A
personal  collection  of  childhood  tuberculosis
literature  was  also  scanned,  particularly  for
earlier literature, and bibliographies of identi-
fied papers searched for additional references.
Papers quantifying the occurrence of ADIH in
children  in  any  manner  are  included;  this
might mean, in some instances, the regular
determination  of  serum  transaminases  and
bilirubin or may refer only to the documenta-
tion of jaundice. Papers relating primarily to
hepatotoxicity  in  adults  have  also  been
reviewed, particularly regarding the principles
underlying hepatotoxicity. Papers in English,
German,  French,  Italian  and  Spanish  were
included. Unless otherwise stated drugs were
administered daily and dosages are given as
mg/kg implying that this is the daily dosage.
The terms hepatotoxicity, hepatitis, liver dam-
age and liver injury are used interchangeably
in  the  literature,  but  for  purposes  of  this
review the term ADIH has been adopted and
indicates any significant deviation from nor-
mal  in  liver  function  tests  (LFT)  or  clinical
signs  that  indicate  liver  dysfunction  in  the
presence  of  antituberculosis  treatment.
Importance is placed on the identification of
jaundice  as  an  indisputable  clinical  sign  of
serious  hepatic  pathology.  Data  relating  to
ADIH  under  different  circumstances  was
extracted  from  relevant  papers  and  summa-
rized under three headings: case reports, the
use of INH, RMP and PZA in chemoprophylax-
is and the use of the same agents in tuberculo-
sis treatment. Account was taken of different
drug dosages, especially that of INH, however
classification as regards dosage is imprecise
as many authors give a dosage range without
indicating the mean or median dosage. 
Several definitions of ADIH and approaches
to  possible  ADIH  appear  in  different  texts
including  those  of  the  American  Thoracic
Society (ATS),2 the Council for International
Organizations  of  Medical  Sciences3 and  the
World  Health  Collaborating  Centre  for
International Drug Monitoring.4 These defini-
tions  have  not  been  applied  to  papers
reviewed, but the opinions of authors accepted
as to what constituted ADIH. Each laboratory
has its own normal values, these are seldom
provided and there is little uniformity as to the
definition of ADIH. 
Results
Before any discussion of ADIH it is relevant
to note that liver biopsy studies and autopsies
reveal that a significant proportion of adults,
before  and  after  antituberculosis  treatment
commencement,  have  hepatic  abnormalities
including granulomata, histiocytic nodules and
non-specific  reactive  hepatitis.5-8 The  role
these abnormalities might play in the develop-
ment of symptoms and signs of ADIH during
chemotherapy  must  remain  speculative.
Similar studies in children have been reported.
Needle biopsy of the liver in 120 children (age
range 31/2 months to 14 years), with different
forms of primary tuberculosis, produced histo-
logical evidence of bacillary dissemination in
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17%  of  children.9 Among  71  children  with
uncomplicated primary tuberculosis, tubercles
were  noted  in  four  and  epithelioid  nodules,
consisting mainly of histiocytes, fibrocytes and
lymphocytes, in eight cases; in 46 with more
serious forms of disease, tubercles were seen
in two children and histiocytic nodules in a
further  three.  Similar  results  have  been
described by others.10,11
It should also be noted that LFT performed
before the start of treatment or chemoprophy-
laxis may be abnormal in a significant propor-
tion of adults and children; this is particulary
likely with more severe disease.12-16 A recent
official statement of the ATS also pointed out
that individual transaminase values may vary
as much as 45% during a single day or 10-30%
on successive days.2
INH was introduced in 195217,18 and brought
about an unprecendented rapid improvement
in  tuberculosis  patients.  Following  its  intro-
duction  for  chemoprophylaxis,  studies
enrolling  several  thousands  of  participants
were  undertaken.19 This  enthusiasm  was
dampened when hepatitis was reported in 19
individuals  from  Baltimore,  USA,  receiving
prophylactic INH; jaundice developed in 13 and
2 died.20 It was later noted that Baltimore City
experienced a simultaneous increase in liver
cirrhosis deaths during this period, creating
an excessively negative picture of the hepato-
toxic propensity of INH.21 None the less these
events led to a reassessment of the hepatotox-
icity of INH and questioned the wisdom of INH
chemoprophylaxis.22 It was soon apparent that
in  any  group  receiving  INH  for  tuberculosis
disease management, or chemoprophylaxis, a
significant  proportion  developed  signs  and
symptoms  of  ADIH.23-27 With  hindsight  early
INH animal studies did demonstrate liver dam-
age28 and early case reports documented liver
damage and jaundice associated with INH use
(and  overdosage);29-34 studies  of  series  of
patients receiving INH revealed increases in
AST,  ALT  and  disorders  of  other  LFT.35,36
Rereading documentation of early chemopro-
phylaxis studies also reveals cases of jaundice,
the significance of which was not appreciat-
ed.37
When INH hepatotoxicity was recognized it
was already known that exposure to INH and
its  metabolites  varied;  there  were  probably
three  N-acetyltransferase  2  (NAT2)  pheno-
types, rapid, intermediate and slow acetylators
of  INH  and  there  was  great  interest  in  the
NAT2  phenotype  in  relation  to  ADIH.  With
definitive  genotyping  it  is  now  indisputable
that SS acetylators of INH are more likely to
experience a rise in serum hepatic transami-
nases than rapid acetylators.38-41 Whether this
translates into susceptibility to overt hepato-
toxicity with all the manifestations of jaundice
and liver failure is less obvious, although some
investigators have identified slow acetylators
as also being more susceptible to severe hepa-
totoxicity.42 By contrast the incidence of hepa-
totoxicity with jaundice in a series of clinical
trials in Chennai, India, over a 20 year period
was 1.9% amongst 1757 patients phenotyped
as slow INH acetylators and 1.2% amongst 1238
rapid acetylators; the difference was not signif-
icant.43 Similarly  in  a  randomized,  double-
blind, placebo-controlled INH chemoprophylax-
is trial 20 838 individuals received INH and
6991 placebo.26 Ninety five cases of hepatitis
occurred in the INH group, but only 7 in the
placebo group; the difference was highly sig-
nificant;  furthermore  75  of  the  INH  group
became jaundiced, but only 5 in the placebo
group.  The  individuals  who  developed  ADIH
were phenotyped as regards their NAT2 status
and the distribution of rapid and slow acetyla-
tors was 50:50 which was that expected in the
Middle European population evaluated. 
Following the introduction of INH there was,
initially, little awareness of possible ADIH com-
plicating  antituberculosis  chemotherapy  in
children. Early descriptions of INH therapy in
children by experienced clinicians also record
dosages  of  INH,  calculated  as  mg/kg  body
weight varying from 10-15 mg/kg body weight44
to 20 mg/kg and higher45-47 and there is fre-
quent comment that children do not experi-
ence undue toxicity. Similarly reports of INH
chemotherapy  trials  during  which  children
received INH in dosages of 5 or 10 mg/kg made
little  comment  regarding  possible  ADIH.48-50
With the introduction of RMP and PZA, also
potentially hepatotoxic agents, much greater
concern emerged regarding ADIH in children. 
The role of RMP in ADIH is still subject to
considerable  discussion.  In  guinea  pigs  and
mice no hepatic lesions were demonstrable fol-
lowing RMP administration.51 In earlier exper-
iments with rats RMP alone caused no hepatic
damage, however the addition of INH caused
major  histological  lesions  in  the  liver.52
Several  adult  studies  compared  experience
with RMP combined with INH and with EMB.
Amongst  pulmonary  tuberculosis  patients
treated for the first time with INH and RMP
some disturbance of LFT was noted amongst 13
(35%) of 37; amongst 72 retreatment patients
given RMP and EMB only 6 (8%) developed a
transient rise in transaminase values and one
a  rise  in  serum  bilirubin.53 Later  the  same
group described 110 previously untreated pul-
monary tuberculosis patients receiving  INH
and RMP and a transient rise in transaminase
values  occurred  in  21  (23%)  and  a  rise  in
serum  bilirubin  in  8  (11%).54 An  extensive
review of RMP published in 1971 summarized
experience with RMP hepatotoxicity following
monotherapy and as part of multidrug therapy;
amongst 1366 individuals receiving RMP mon-
therapy  5  (0.37%)  became  jaundiced  and  1
(0.07%)  developed  biochemical  abnormali-
ties;55amongst 4280 patients treated with RMP
and  other  drugs,  including  INH,  80  (1.87%)
developed  jaundice  and  another  27  (0.6%)
other  biochemical  abnormalities.  The  case
report  of  Askgaard  et  al.  also  provides  an
instructive window on the interplay of INH and
RMP  in  ADIH.56 Precisely  why  RMP  should
have  such  a  deleterious  influence  on  INH
hepatotoxicity is uncertain; RMP may induce
INH hydrolase and thus increase the amount
of INH directly converted to isonicotinic acid
and hydrazine; slow acetylators of INH might
then be more exposed to hydrazine and hepa-
totoxicity.57
In  1954  McDermott  et  al  enthusiasticaly
described experience with INH and PZA com-
bined in daily dosages of 5 mg/kg and 50 mg/kg
respectively given twice daily.58 Of 53 patients
with  3  month  and  6  month  bacteriological
results 92% remained culture negative; unfor-
tunately  hepatitis  occurred  in  six  (10%)
patients, four became jaundiced and one died
of fulminant hepatitis. The first four cases of
hepatitis  occurred  during  the  5th  month  of
treatment and the PZA treatment duration was
shortened to 90 days, but the fatal hepatitis
case occurred at 55 days treatment and PZA
use was stopped altogether. A later study by the
same group gave PZA in a lower dosage of 20-
30 mg/kg, however efficacy was also lower and
the risk of hepatotoxicity was not eliminated.59
However  when  PZA  was  studied  at  daily
dosages  of  30-40  mg/kg  together  with  other
drugs  in  British  Medical  Research  Council
(MRC) trials the incidence of ADIH was low: 3
(0.2%) of 1845 patients in East and Central
Africa,  13  (0.6%)  of  2219  patients  in  Hong
Kong  and  11  (2.8%)  of  397  patients  in
Singapore.60 The demonstration of the unique
sterilizing capacity of RMP and PZA revolution-
ized antituberculosis regimens and introduced
six months short-course chemotherapy.61 The
identification of the first two months of thera-
py as critical for the action of PZA in combina-
tion  with  the  powerful  sterilizing  activity  of
RMP led to the evaluation of this combination
for two month chemoprophylaxis regimens. An
early study of two months RMP and PZA, how-
ever, found a significant incidence of adverse
events  that  contributed  to  non-compliance,62
but larger studies in HIV-infected patients of
the combination of RMP and PZA given daily63
or twice weekly64,65 in comparison to INH also
given daily or twice weekly, suggested that the
RMP/PZA combination was both safe and effi-
cacious and it was recommended by the ATS.66
Unfortunately  further  studies  found  the
combination of RMP and PZA to be associated
with an unacceptable incidence of ADIH;67-71
and Lee et al.  emphasized the need for careful
monitoring  of  patients  receiving  RMP  and
PZA.72 Some  studies  also  included  a  small
number of children. Kandula et al. managed 10
children with two months RMP/PZA; one child
aged  15  years  developed  severe  ADIH.73
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Concerns  regarding  chemoprophylaxis  with
RMP and PZA were confirmed in an extensive
programme  survey  in  the  USA  of  RMP/PZA
usage for latent tuberculosis.74 The incidence
of ALT values higher than X5 normal and ADIH
per 1,000 RMP/PZA initiations was 25.6 (95%
CI 22.3-29.3) and 18.7 (CI 15.9-21.9) respec-
tively;  there  were  seven  fatalities  (rate  0.9)
and  23  hospitalizations  (rate  2.8  per  1,000
RMP/PZA initiations). Hong Kong researchers
also presented a cohort and nested case study
of pulmonary tuberculosis management with
combinations  of  INH,  RMP  and  PZA;  adding
PZA to INH and RMP during the continuation
phase  of  therapy  increased  the  ADIH  risk
appreciably.75 None the less some studies of
adults76 and children77 have reported accept-
able  levels  of  hepatotoxicity  associated  with
the chemoprophylactic use of 2 months of RMP
and  PZA  and  emphasized  the  advantages  of
improved compliance with shorter regimens. 
Le Bourgeois et al. studied PZA in 42 chil-
dren receiving a mean dosage of 23.3 mg/kg
(range 20-37 mg/kg) with INH and RMP at rec-
ommended dosages.78 AST and ALT values at 1
month  and  at  treatment  conclusion  rose  to
more than X3 normal in only 2 children (5%);
treatment  was  not  interrupted  and  the
increased values normalized. Sánchez-Albisua
et al. described the use of PZA (20-25 mg/kg),
INH  (10  mg/kg)  and  RMP  (15  mg/kg)  in  a
cohort of 114 children. Eleven children (19.6%)
with normal ALT values before treatment expe-
rienced  an  increase  in  values;  however  the
highest value was 193 U/L and only four chil-
dren had values > 65 U/L.79 In a retrospective
study from Japan 99 children aged 0-16 years
treated for tuberculosis were assessed.80 In 22
children  (22.2%)  AST  or  ALT  values  were
increased, but < X5, the upper limit of normal;
severe ADIH, (an elevation of AST or ALT val-
ues to more than X5 normal in those with nor-
mal  values  pre-treatment),  occurred  in  8
(8.1%) children, and young age and PZA use
were associated with ADIH. It should be noted
that only 12 children received PZA in this study
and  that  4  were  amongst  those  developing
ADIH and that 4 of these 8 children had severe
disease in the form of tuberculous meningitis.
In univariate analysis disease severity was an
ADIH risk factor, but not in multivariate analy-
sis. A single case report also suggested that
RMP  and  PZA  combined  might  have  con-
tributed  to  serious  ADIH  in  a  10  year  old
child.81 
The influence of infectious
hepatitis
Viral  infectious  hepatitis,  is  common  in
developing countries, may predispose to ADIH,
and be confused with ADIH and thus have a
significant influence on the interpretation of
results  of  many  studies.82-85 The  ATS,  in  a
review of ADIH, concluded that it was not pos-
sible to reach firm conclusions about the role
of hepatitis B virus infection in precipitating
or exacerbating ADIH.2 HIV-infection and its
treatment add another element to this prob-
lem. In a cohort of African patients receiving
antiretroviral  therapy,  although  there  was  a
low  incidence  of  hepatotoxicity,  carriage  of
HBsAg and antituberculosis therapy increased
the  risk  of  hepatotoxicity  significantly.86
Türktas et al. studied infectious forms of hepa-
titis amongst 705 adult Turkish tuberculosis
patients.87 Serologic markers (IgM) for viral
hepatitis  were  studied  amongst  57  (8.1%)
patients who developed acute ADIH with jaun-
dice during treatment with INH and RMP and
confirmed hepatitis B in 6 (10.5%) patients,
while 4 (7%) were hepatitis C positive. Four
patients (7%) were HBsAg-positive, and this
was within the range reported for Turkey. The
authors comment that the reported incidence
of ADIH is often higher in developing coun-
tries, but that not all cases of hepatitis during
antituberculosis  treatment  may  be  due  to
ADIH.  Similar  conclusions  were  drawn  by
other researchers88 and three recent studies
from India have also identified viral hepatitis
as a common complicating factor in 10-15% of
patients presenting with apparent ADIH.89-91
With regard to children early reports of pos-
sible INH ADIH often carried suggestions that
infectious  hepatitis,  or  other  intercurrent
infections,  might  mimick  INH  ADIH  or
increase susceptibility to ADIH.12,92-95
Dieu,  after describing a high jaundice inci-
dence amongst his patients discusses the sub-
ject at length and, in the absence of epidemio-
logical evidence of an infectious hepatitis out-
break in the relevant ward, considered this an
unlikely explanation for the high incidence of
severe ADIH encountered.93 Several reports of
ADIH also document infectious forms of hepa-
titis in children presenting with jaundice while
receiving  antituberculosis  treatment.16,96,97
Such forms of hepatitis are particularly likely
in  children  hospitalized  with  more  serious
forms of tuberculosis for a prolonged period.
Kumar et al. studied serological markers for
hepatitis  viruses  amongst  40  children  who
developed ADIH characterized by jaundice and
raised serum ALT and bilirubin during INH and
RMP therapy, both in dosages of 10-20 mg/kg
body  weight  daily.98 Hepatitis  A  and  B  were
shown to be associated with apparent ADIH in
7.5%  and  35%  of  children  respectively.
Epidemiological evidence suggested that non-
A and non-B viruses could have been responsi-
ble for hepatitis amongst at least some of the
remaining 23 children. The authors conclude
that the high ADIH incidence reported from
some  developing  countries  may  be  due  to
infectious  forms  of  hepatitis;  the  risks  for
infection being exacerbated by poor hygiene
and the need for parenteral therapy in severe-
ly  ill  children.  As  the  fatality  rate  was  20%
amongst the 40 children described the problem
has  serious  implications.  Studies  by  Dieu,
Burghard, Ramachandran, Rugamini & Mehta,
Tsagaropoulou -Stinga et al.99-103 all reported
very  high  incidences  of  jaundice  associated
with high dosages of INH and RMP, but others
using equally high INH and RMP dosages have
not experienced this level of serious liver dis-
ease.16,104,105 Part  of  these  reported  differ-
ences may well be due to the occurrence of
undetected infectious hepatitis.
Antituberculosis drug-induced
hepatotoxicity in children
There is now no doubt that children experi-
ence ADIH and 26 papers summarized in Table
1 give details of possible ADIH in 33 children.
While evidence supporting ADIH in some cases
might be regarded as flimsy, there are several
cases,  where  rechallenge  with  the  relevant
agent confirmed the etiology. The median age
of  children  was  five  years  and  eight  (24%)
received an INH dosage of 20 mg/kg or more,
five  (15%)  a  dosage  of  15  mg/kg  and  the
remaining 19 (58%) 10 mg/kg or less. A recent
report  describes  a  further  20  children  (0-17
years) who experienced fulminating INH-relat-
ed  hepatic  failure;129 in  this  last  report  the
median age of the children was 10.5 years and
all the dosages of INH were <12 mg/kg (6 not
available). An earlier paper reviewed possible
INH related deaths in the USA between 1965-
1989, and identified 14 cases <20 years of age,
but these probably also include older adoles-
cents and may well include cases described in
this present review.130
It must be emphasized that a common theme
in these reports is the frequency with which
INH treatment, either alone or accompanied by
RMP and PZA, was continued in the face of
symptoms indicating possible ADIH. 
ADIH in children receiving
chemoprophylaxis
Eighteen  papers  record  INH  chemopro-
phyalxis in children and comment on adverse
events.  Seven  give  details  of  2149  children
receiving an INH dosage of 4-6 mg/kg; serum
transaminase values were determined regular-
ly in 461children and 56 (12.1%) had increased
values;  treatment  was  discontinued  in  five
(0.23%), no child developed jaundice.77,131-136
Four  studies  enrolled  1451  children  who
received an INH dosage of 10 mg/kg;121,137-139
of 369 whose LFT were routinely determined
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25  (6.8%)  had  increased  values.  Jaundice
developed  in  1  child  (0.07%),  symptoms  or
signs indicative of ADIH were experienced by
64 (4.4%), but treatment was stopped in only 2
(0.14%).
An INH dosage of 10-20 mg/kg was adminis-
tered in 7 studies enrolling 7528 children.140-
146 No child became jaundiced and only four
(0.05%)  had  symptoms  or  signs  of  ADIH.
Details of LFT were provided by Rapp et al. and
17 (14.7%) of 116 children had abnormal val-
ues.142 In the study of Byrd et al. details are not
provided  but  LFT  were  determined  monthly
and  no  child  had  values  more  than  X5  nor-
mal.143 Two papers record RMP use alone in
chemoprophylaxis for 182 children and adoles-
cents.77,147 Both  studies  recorded  liver  func-
tions  and  found  values  above  normal  in  11
(6.04%); all were asymptomatic, but RMP was
stopped in one adolescent with ALT values >X2
normal. The study of Lardazibal et al. recorded
no cases of hepatitis amongst approximately
166 individuals aged 1-24 years receiving four
months  RMP  for  chemoprophylaxis,  but  the
precise ages of participants are not given.148
For  comparison  the  use  of  RMP  alone  for
chemoprophylaxis amongst adults is recorded
in 3 studies;149-151 very low rates of ADIH were
also  found.  In  the  study  of  the  Hong  Kong
Chest  Service  no  difference  was  found  in
mean LFT values of patients receiving RMP or
placebo;149 Polesky et al. recorded no sympto-
matic ADIH 150 and in the study of Menzies et
al. no patients experienced a significant rise in
transaminase values.151 Further evidence that
RMP is responsible for significantly less hepa-
totoxicity than INH is provided by Menzies et
al. (2008).152 Of 422 individuals receiving INH
chemoprophylaxis 16 (3.8%) developed grade
3-4  hepatitis  compared  to  3  (0.7%)  of  418
receiving RMP (P=0.003).
In four papers the use of INH and RMP, both
at a 10 mg/kg dosage, in 1301 children 0-15
years  is  described;139,153-155 in  the  study  of
Wales et al. the RMP dosage was 10-15 mg/kg.
In 13 (1%) children symptoms of nausea, vom-
iting  or  epigastric  pain  occurred,  but  in  no
case was treatment interrupted.153 Liver func-
tion tests were not routine in any of the stud-
ies, but in the study of Wales et al. a transient
rise in transaminase values occurred in eight
children. The authors also record the use of
INH and RMP chemoprophylaxis in another 46
children during a school outbreak of tuberculo-
sis without adverse events.
Three papers describe two months RMP (10
mg/kg) and PZA (15-30 mg/kg) for chemopro-
phylaxis in 97 children.73,77,134 Magdorf et al.
evaluated liver functions pre-treatment and at
one and two months after starting treatment;
although mean values increased no children
had  abnormal  values.77 One  of  11  children
aged 15 years in the study of Kandula et al.
developed an asymptomatic increase in ALT to
X5 normal values and treatment was stopped.73
The liver enzymes were studied fortnightly in
23 adults, but this was not always possible in
the  children,  although  they  were  seen  and
examined  fortnightly;  amongst  the  adults  4
(17.3%) developed ADIH. Tortajada et al. stud-
ied 56 children 0-19 years of age and 213 adults
and  liver  enzymes  were  determined  at  two,
four, six and eight weeks after starting treat-
ment.134  No child had grade 3 or more ADIH
and none had any signs or symptoms of ADIH.
Amongst 213 adults enrolled ADIH occurred in
20 (9.4%). The numbers of children enrolled in
these last three groups of studies are relative-
ly  small,  but  provide  little  indication  of  any
serious risk of ADIH in comparison to experi-
ence in adults.2 Table 2 is a condensed sum-
mary of all studies documenting ADIH associ-
ated  with  chemoprophylaxis.  Abnormal  LFT
were recorded in 110 (9.0%) of 1225 children
evaluated,  jaundice  occurred  in  one  child
(0,01%) of the 12,708 studied and treatment
was discontinued in eight (0.06%) children.
Hepatotoxicity of
Antituberculosis agents in 
children treated for tuberculosis
Despite initial complacency regarding hepa-
totoxicity  the  introduction  of  RMP  and  later
PZA  into  routine  treatment,  together  with
reports of hepatotoxicity in adults, created cir-
cumspection  in  managing  children;  from
approximately  1970  reports  of  treatment  of
children with tuberculosis disease frequently
refer to LFT evaluation or the occurrence of
jaundice in children receiving INH, RMP and
PZA. In this review 69 papers are referenced
giving details of children treated for tuberculo-
sis that evaluate or comment on ADIH. 
The majority of papers document daily ther-
apy,  but  partial  or  total  intermittent  therapy
was  described  in  several  papers.97,156-163 In
general, intermittent regimens were associat-
ed with less hepatotoxicity, but were also fre-
quently used for less serious forms of tubercu-
losis. 
Two  papers  report  early  studies  in  which
INH monotherapy was used to manage tuber-
culosis disease in 218 children;163,164 in only
one were liver functions studied and four of 50
(8%)  children  had  increased  LFT  values.164
One child (0.46%) developed jaundice. 
Thirteen studies recorded treatment of 3053
children with INH dosages of 10-20 mg/kg and
drugs  other  than  RMP.12,102,156,163,165-173 The
additional drugs commonly used were SM, PAS
and EMB and in one study PZA.172 Jaundice
occurred  in  12  children  (0.39%);  serum
transaminase  values  were  routinely  deter-
mined  in  443  children  and  increased  in  49
(11.1%). There were several interesting obser-
vations. Mantero et al. phenotyped 54 children
as rapid (22) or slow (32) INH acetylators; of
14  children  developing  increased  AST  levels
only two (9.1%) were rapid INH acetylators and
12 (37.5%) slow, suggesting an influence of
INH  concentrations  on  ADIH.170 Jaundice
occurred in 12 children and in nine this was
associated with INH dosages of ≥20 mg/kg and
in 1 case ≥15 mg/kg; it is noteworthy that eight
of 12 cases of jaundice were reported in one
study.169 Three papers give details of the man-
agement of children with INH 8-15 mg/kg and
RMP.99,174,175 All 224 children entered in these
studies had AST and ALT regularly evaluated
and  32  (14.3%)  had  increased  values  on  at
least  one  occasion.  Two  children  (0.9%)
became jaundiced99 and three (1.3%) experi-
enced symptoms compatible with ADIH. The
study of Dieu  is frequently referrenced regard-
ing the interaction of INH and RMP and the
influence of increased INH dosages.99
Seven studies record details of 453 children
receiving INH dosages of 10-20 mg/kg together
with  RMP,  but  no  other  agents.99,100,102,
156,158,169,176AST and ALT levels were not report-
ed in 3 studies and amongst the remaining 5
studies  413  children  were  evaluated  and
increased  AST  or  ALT  values  found  in  64
(15.5%).  Jaundice  occurred  in  52  children
(11.5%). The percentage of children with jaun-
dice  is  high  and  strongly  influenced  by  the
studies of Dieu,99 Burghard et al.,100 Bassetti
et al.176 and Rugamini & Mehta.102 However,
whether or not infectious causes of hepatitis
underlie some of these cases, it remains true
that the incidence of jaundice was influenced
by  the  INH  dosage;  the  studies  of  Dieu,99
Burghard et al.100 and Rugamini & Mehta 102
provide evidence that reducing the INH dosage
to a maximum of 15 mg/kg has a considerable
influence on susceptibility to severe ADIH. 
Sixteen papers describe the findings in 2714
children receiving an INH dosage of approxi-
mately 10 mg/kg (range 5-14 mg/kg), together
with RMP and other agents.13,78,80,94,157,161,177-
186 In  four  studies  LFT  were  not  evaluated;
amongst 1762 children regularly evaluated 141
(8.0%) had increased transaminase levels and
amongst  the  whole  group  jaundice  was
observed in three children (0.11%). Symptoms
or clinical signs of ADIH were observed in 35
children (1.3%).
Nine  studies  enrolled  2332  children  who
received an INH of dosage 10-20 mg/kg togeth-
er with RMP and other drugs.160,171,172,186-191 In
two  studies  LFT  were  regularly  evaluated  in
1406  children;187,189 AST  and  /or  ALT  levels
were  increased  in  139  (9.9%).  Jaundice
occurred in five (0.22%).
Fifteen papers described 717 children treat-
ed for TBM; in four 259 children received INH
dosages of 10-15 mg/kg.12,101,192,193 In only one
study were LFT determined and these children
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were  probably  treated  with  INH  alone.12
Amongst these 14 eight (57%) had increased
LFT levels before treatment and at four weeks
after  treatment  commencement  four  (29%)
still had increased values. The author implies
that  the  only  children  with  abnormal  values
were  those  with  increased  values  pre-treat-
ment. He also describes 9 of 21 children treat-
ed with INH who developed measles or varicel-
la and in whom LFT increased by a factor of X4
to X6 normal values, but INH was continued
without any deleterious effects. 
Jaundice  was  reported  in  26  children
(10.04%) and all 26 cases come from the stud-
ies of Ramachandran et al.101 and Parasarathy
et al.192 In the study of Parasarathy et al. ADIH
was  almost  entirely  confined  to  patients
(adults  and  children)  receiving  INH  and
RMP.192 When ADIH did occur it was mainly in
the  intensive  phase  and  was  also  more  fre-
quent  in  phenotypically  slow  acetylators  of
INH,  implying  that  exposure  to  higher  INH
concentrations  plays  a  role  in  ADIH.  When
RMP was given intermittently the incidence of
jaundice was also lower. The authors also point
out that viral hepatitis is endemic in South
India; both INH and RMP might contribute to
exacerbating  subclinical  viral  hepatitis  and
this effect could be more marked with higher
drug dosages. 
Eleven papers described 458 children treat-
ed for TBM with INH dosages ranging from 15-
20  mg/kg.16,96,101,103-105,168,192,194,195,196 Again  a
very high proportion (174; 52.9%) of 329 chil-
dren in whom concentrations of transaminas-
es  were  determined  had  increased  values.
Review
Table 2. Antituberculosis drug-induced hepatotoxicity in children receiving chemoprophylaxis.
Dosage mg/kg Studies n Liver function tests  Symptoms of Jaundice Treatment 
discontinued abnormal hepatotoxicity
INH Chemoprophylaxis
INH 4-6  7 2149 56/461 (12.1%) 2 (0.05%) 0 5 (0.23%)
INH 10  4 1451 25/369 (6.8%) 64 (4.4%) 1 (0.07%) 2 (0.14%)
INH 10-20  7 7528 17/116 (14.7%) 4 (0.05%) 00
18 11128 98/946 (10.4%) 70(0.63%) 1 (0.01%) 7(0.06%)
RMP containing chemoprophylaxis regimens
RMP 10  2 182 11/182 (6%) 00 1 (0.55%)
INH 10, RMP 10  4 1301 Not routinely measured 13 (1.0%) 0/1301 0
RMP 10 PZA15-30 3 97 1/97 (1%) 0/97 0/97 0
All forms of chemoprophylaxis
27 12708 110/1225(8.0%) 83 (0.65%) 1 (0.01%) 8(0.06%)
INH, isoniazid; PZA, pyrazinamide; RMP, rifampicin.
Table 3. Antituberculosis drug-induced hepatotoxicity in children treated for tuberculosis.
Drugs INH Dosage Studies N Liver function tests abnormal Symptoms or 
mg/kg signs of liver disease 
INH 6-10 2 218 4/50         (8.0%) Jaundice in 1   (0.46%)
INH & other agents <10-20  13 3053 49/443   (11.1%) Jaundice 12     (0.39%)
INH & RMP 8-15 3 224 32/224    (14.3%) Symptoms of ADIH 3   (1.3%). 
Jaundice 2         (0.89%).
INH & RMP 10-20  7 453 64/413    (15.5%) Jaundice 52     (11.5%).
INH & RMP and other agents 5-14 16 2714 141/1762 (8.0%) Symptoms of ADIH 35  (1.3%). 
Jaundice 3          (0.11%)
INH & RMP and other agents 10-20 9 2322 139/1406 (9.8%) Symptoms of ADIH 6   (0.26%). 
Jaundice 5          (0.22%)
50 8984 380/3855 (9.9%) Symptoms of ADIH 32 (0.36%) 
Jaundice 75        (0.91%)
Tuberculous meningitis
INH, RMP and other agents 10-15  4 259 Not routinely determined Other drugs substituted 23 (8.9%). 
Jaundice 26   (10.0%)                 
INH, RMP and other agents 10-20 11 458 174/329 (52.9%) Jaundice 46   (10.0%)             
15 717 174/329 (52.9%) Jaundice 72/717  (10.04%)                
INH, isoniazid; RMP, rifampicin.
Table  4.  Selected  studies  of  adults  with
tuberculosis  receiving  INH  and  RMP
recording an increase in transaminase val-
ues above normal 
Authors n Increased
transaminase
values
Leeset al.197153 105 37 (35%)
Lalet al. 1972201 63 14 (22%)
Lees et al.197254 110 21 (23%)
Grönhagen-Riska 1978202 319 58 (18%)
Musch et al. 198242 86 30 (34%)
Hwang et al. 199783 240 63 (26%)
Agal et al. 2005203 200 221 (11%)
1123 244 (22%)[page 58] [Pediatric Reports 2011; 3:e16]
Jaundice was also reported in a high propor-
tion, affecting 46 (10.04%) and in the studies
of  Rahajoe  et  al.,168 Ramachandran,101
Tsagaropoulou-Stinga et al.103 and Parasarathy
et al.192 the proportion of children becoming
jaundiced varied from 29% to 50%; other stud-
ies using similar regimens with equally high
drug dosages, although reporting a high pro-
portion of children with increased transami-
nase values16,96,104,105,194 found a much lower
incidence of jaundice or no cases of jaundice. 
Table 3 summarizes ADIH amongst children
treated  for  tuberculosis  disease.  Excluding
TBM, 8984 children were treated for disease
with jaundice reported in 75 (0.83%); LFT were
evaluated in 3855 children and were abnormal
in 380 (9.9%). TBM treatment was recorded for
717  children  and  jaundice  occurred  in  72
(10.04%) and abnormal LFT in 174 (52.9%) of
329 children. The study of Diekoff  was not
included in the tabulation of LFT results due to
the early methodologies used.12
Discussion
The most important finding of this review is
that  ADIH,  however  defined,  occurs  in  chil-
dren, but that  the incidence is lower than in
adults receiving comparable drug dosages and
regimens. The contrast between children and
adults is clearest in chemoprophylaxis studies
enrolling  children  and  adults  in  the  same
study.  Amongst  children  approximately  10%,
receiving either INH alone or INH accompa-
nied by RMP or RMP and PZA, experience a
rise in serum transaminase values or (in older
studies) an abnormality in LFT. Less than 1%
are recorded as having symptoms of ADIH and
only 1 child amongst more than 12,000 receiv-
ing  INH  chemoprophylaxis  is  recorded  as
developing jaundice. Very similar results are
found amongst much smaller numbers of chil-
dren  receiving  RMP  containing  prophylactic
regimens.  As  regards  PZA  only  97  children
entered in 3 studies are recorded who received
PZA with RMP for chemoprophylaxis, but the
risk of ADIH does not appear serious.
Amongst  children  treated  for  tuberculosis
disease a different picture emerges. Although
a similar proportion of children (approximate-
ly 10%) experience increased serum transami-
nase values, a considerably larger proportion
presented with jaundice than amongst those
managed for latent infection; this proportion
varies from less than 1-50% in some studies of
children treated for TBM. Several factors may
be important in this regard.
Disease severity plays a role in the frequen-
cy of ADIH91,171 and underlying hepatic abnor-
malities  present  in  both  adults5-8 and  chil-
dren9-11 before the start of treatment, especial-
ly in disseminated forms of tuberculosis, may
be relevant in this regard; a large proportion of
children will also have abnormal LFT before
treatment.  This  is  particularly  likely  in  chil-
dren  with  disseminated  disease  that  might
accompany TBM.  The study of Dieckhoff 12
found no abnormal LFT amongst children with
uncomplicated  primary  tuberculosis  prior  to
treatment, but abnormal LFT amongst 57% of
14 children with TBM not complicated by mil-
iary tuberculosis and 68% of 63 children with
miliary tuberculosis without TBM. 
In regimens including INH and drugs other
than RMP there are indications that the INH
dosage may play a role in ADIH: of 12 cases of
jaundice  reported  following  the  use  of  INH
with drugs other than RMP, 9 occurred in chil-
dren receiving an INH dosage of 20 mg/kg or
higher.102,168,169 With regard to children receiv-
ing only INH and RMP a number of authors
commented on a reduced incidence of severe
ADIH and jaundice, when the INH dosage was
reduced to less than 15 mg/kg99-101,168,169,192,196
or less than 10 mg/kg.102 Amongst the 3 studies
giving details of 224 children treated with only
INH and RMP and receiving an INH dosage of
approximately 8-15 mg/kg, only 2 (0.9%) chil-
dren became jaundiced99,174,175 compared to 52
(11.5%)  of  453  children  receiving  INH  in
dosages  of  10-20  mg/kg.99,100,102,156,158,169,176
Turning to those studies where INH and RMP
were  combined  with  other  agents,  often
including  PZA,  jaundice  occurred  in  only  2
(0.07%) of 2714 children receiving RMP and
INH  in  a  dosage  of  approximately  10
mg/kg13,79,80,94,157,161,177-185 and  5  (0.21%)  of
2413 children receiving an INH dosage of 10-20
mg/kg, which does not suggest an influence of
INH dosage.171,172, 186-191There is also not a sig-
nificant influence of dosage regarding those
with  increased  serum  transaminases;
increased values were reported in 141 (8%) of
1762 children receiving an INH dosage of 10
mg/kg and 139 (9.8%) of 1406 children receiv-
ing dosages of 10-20 mg/kg. 
However  support  is  lent  to  the  risk  of
increased  concentrations  of  INH,  or  its
metabolites, by the finding that, as in adults,
children who are phenotypically slow acetyla-
tors of INH were more likely to experience a
rise in transaminase values above normal.170
In the study of Martinez-Roig et al. all children
presenting  with  clinical  signs  and  raised
enzyme values were phenotypically slow INH
acetylators.178 The importance of INH dosage
in  precipitating  severe  hepatotoxicity  also
receives support from adult studies.197 In con-
trast  to  INH,  the  dosage  of  RMP  does  not
appear to be a critical factor in precipitating
hepatotoxicity,93,99 although  O’Brien  et  al.
found that RMP dosage became a significant
factor  in  hepatotoxic  reactions  indicated  by
AST values above 100 U/L or increased serum
bilirubin.171 Several  paediatric  studies  of
groups of similar children receiving INH, both
with  and  without  RMP,  suggest  that  merely
adding RMP to the regimen was sufficient to
precipitate severe hepatotoxicity.102,166-169,196
PZA is an acknowledged hepatotoxic agent
but few publications have addressed its poten-
tial to cause ADIH in children; a single case
report suggested that RMP and PZA combined
might have contributed to serious ADIH in a 10
year old child.81 Two studies of the combina-
tion  of  INH,  RMP  and  PZA  for  chemothera-
py78,79 found no evidence that PZA constituted
an hepatotoxic risk, but a retrospective study
found the use of PZA associated with AST or
ALT values >X5 the upper limit of normal, but
only 8 of 90 children received PZA and several
of these children had more severe disease.80
In considering the role of PZA it is also of
interest  that  PZA  was  not  used  in  studies
reporting particularly high incidences of jaun-
dice during the treatment of TB, although it
was  used  in  several  studies  using  similarly
high dosages of INH and RMP during which
jaundice  was  unusual  or  did  not  occur.16,96,
104,105 It should also be noted that several liter-
ature reviews concluded that the risk of hepa-
totoxicity associate with PZA dosages of 30-40
mg/kg in adults was not excessive.198-200
Comparisons of the results of this review
with  those  of  adults  receiving  similar  regi-
mens for tuberculosis disease treatment are
difficult.  ADIH  associated  with  treatment  of
disease  is  more  complex  and  few  studies
include  both  adults  and  children  allowing  a
direct comparison of the same regimens in the
same populations. Amongst groups of children
treated for tuberculosis, other than TBM, the
incidence of increased transaminase values is
approximately 10% and similar to that amongst
children receiving chemoprophylaxis; the per-
centage  of  children  becoming  jaundiced  is,
however,  considerable  higher,  overall  1.2%
compared  to  0.01%  amongst  those  receiving
chemoprophylaxis  and  it  should  be  empha-
sized that this figure is strongly influenced by
very high rates of jaundice in a small number
of studies, in nearly all of which cases the chil-
dren were receiving INH dosages of 20 mg/kg
or 10-20 mg/kg.  
Table 4 summarizes selected studies report-
ing  adult  pulmonary  tuberculosis  patients
receiving  INH  and  RMP  with  documented
increases in serum transaminase values above
the  upper  limit  of  normal  after  the  start  of
treatment;  the  mean  percentage  (22%)  is
approximately twice that in children suggest-
ing a greater propensity for ADIH in adults.
While it might be more valid to consider those
children with transaminase values that were
>X2 or >X3 or >X5 normal this information is
seldom provided.
In the meta-analysis of Steele et al. 6155
adult patients were evaluated in 19 studies and
168  (2.73%)  diagnosed  with  clinical  hepati-
tis.204 In this present review, excluding chil-
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dren with tuberculous meningitis, and accept-
ing the occurrence of jaundice as evidence of
severe ADIH, 70/8984 (0.78%) children devel-
oped severe clinical hepatitis and an addition-
al 31 (0.35%) developed symptoms indicative
of  ADIH.  These  figures  are,  again,  strongly
influenced  by  the  occurrence  of  jaundice
amongst the 453 children receiving INH and
RMP only, with INH in a dosage of 10-20 mg/kg.
Omitting these groups, only 18 (0.36%) cases
of  jaundice  occurred  amongst  8494  children
treated for tuberculosis disease. 
A tentative conclusion of this review might
thus be that INH dosages of 5-15 mg/kg alone
or in the company of other drugs do not consti-
tute  and  undue  risk  for  the  development  of
ADIH in children. 
As regards RMP it seems likely that RMP
itself carries a relatively small risk of ADIH,
but, for reasons not fully understood, can pre-
cipitate ADIH particularly with INH dosages of
>15  mg/kg.  The  dosage  of  RMP  does  not
appear critical in this interaction. From what
is known of the serum concentrations of RMP
achieved  in  children  it  would  appear  that
dosages of 10-20 mg/kg can be safely recom-
mended for children up to the age of 13 years
with a proportionately lower dosage with incre-
ments  in  weight.205 Despite  recent  concern
about the hepatotoxicity of PZA in adults, both
in chemoprophylaxis and in disease treatment,
this review produced little evidence that PZA
makes a major contribution to ADIH in mul-
tidrug regimens in children. In only one study
was there an indication that PZA made a sig-
nificant contribution to ADIH, and this depend-
ed upon the influence of eight children receiv-
ing PZA.80 In several studies the highest inci-
dences of ADIH occurred amongst children not
receiving PZA. The dosage of PZA used in the
studies reviewed varied from 25 mg/kg to 40
mg/kg and there was no suggestion that the
dosage of PZA made any contribution to the
development of ADIH. Thus it is likely that a
PZA dosage of 30-40 mg/kg, with appropriate
adjustments for age, can be recommended for
use in children.  
There  is  little  information  regarding  the
interaction of other infectious diseases in par-
ticular  HIV-infection  and  ADIH  in  children.
Evidence from adults is conflicting at present
and  while  some  studies  suggest  that  HIV-
infected  individuals  may  be  exposed  to  a
reduced risk of ADIH86other studies found that
the risk was unaltered amongst those who are
HIV-infected206,207 and yet other studies found
HIV infection an independent risk factor for
ADIH.88 In  a  recent  randomized  controlled
study of INH prophylaxis in 263 HIV-infected
children serum ALT was raised in 2 (0.02%) of
131 children receiving placebo, but none of the
132 receiving INH.208 Particularly in develop-
ing countries the various forms of infectious
hepatitis play a role in ADIH, both in possibly
precipitating  toxicity  and  in  confusing  the
diagnosis of ADIH. Amongst adults and chil-
dren there is ample evidence that a significant
proportion  of  patients  with  ADIH  may  have
underlying infectious hepatitis87,89-91Amongst 85
Indian patients, mainly adults, presenting with
acute  liver  failure  associated  with  ADIH  15
(17.6%) had associated hepatitis virus infec-
tion.209 In children this combination may be
associated with a high mortality and it is thus
a potentially serious problem.98
Limitations
The papers reviewed stretch back over more
than 50 years and their scientific quality there-
fore varies considerably. The terms hepatotox-
icity, hepatitis, liver damage and liver injury
are used interchangeably and each term could
be debated. In many instances the purpose of
the study was the evaluation of chemoprophy-
laxis or  treatment efficacy; in only a minority
was the purpose the documentation of hepato-
toxicity. Much data relating to ADIH is thus
fragmentary; LFT were seldom performed rou-
tinely in early studies and cases of hepatotoxi-
city might well have been missed or not report-
ed. None the less the occurrence of an out-
standing  event  such  as  jaundice,  or  indeed
death, as result of liver failure in a child, is
most unlikely to have been missed by astute
clinicians. Criteria for suspending treatment
also vary and where some studies follow the
recommendations of the ATS in this respect,
other clinicians, for example, suspended treat-
ment following a two-fold rise in transaminase
values, irrespective of the presence of symp-
toms. Despite these reservations a substantial
body of data has been assembled that may be
valuable  when  assessing  the  risks  of  ADIH
attached to different dosages of INH, RMP and
PZA to be used in children.
In  conclusion  this  review  confirms  that
ADIH does occur in children and that vigilance
is always necessary if the tragedy of acute liver
failure is to be prevented in children. None the
less the incidence of ADIH in children is con-
siderably lower than in adults and the newly
recommended dosages of INH, RMP and PZA
for  children  do  not  appear  to  constitute  an
added risk factor for ADIH. 
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